Dr. Mullen conducts clinical research in Renal Tumors. She is the Children?s Hospital Principal Investigator for multiple Children?s Oncology Group (COG) investigational protocols on the classification and treatment of Pediatric Renal Tumors. She is also Vice-Chair of the COG study on the Biology and Classification of Renal Tumors, and the Vice-Chair of the study of the treatment of Very Low Risk and Standard Risk Wilms Tumor. The ongoing COG studies in renal tumors aim to improve the treatment of children with renal tumors by helping to define which patients need more intensive treatment, and which patients can be spared exposure to some treatments with chemotherapy and radiation therapy.
Focus of Research
Dr. Mullen's research is directed towards understanding the best management for children with pediatric renal tumors. Increased understanding of appropriate risk stratification of patients with renal tumors, and adjustment of therapy based on response during therapy will hopefully lead to better overall cure rates, while minimizing the long term effects of therapy for survivors of pediatric renal tumors. Dr. Mullen is also interested in defining appropriate surveillance testing for patients after completion of treatment for their tumor.
In a cross-discipline collaboration with other faculty members at Children's Hospital and the Dana-Farber (Dr. Hanno Steen/Dr. Alex Kentsis/Dr. Carlos Rodriguez-Galindo,) Dr. Mullen is investigating the use of the technique of urine proteonomics to find urinary markers of renal tumors.
About Dr. Elizabeth Mullen
Dr. Mullen received her BA at Wellesley College, her MD at Yale University, and completed her internship and residency at Boston Children's Hospital. She also completed her fellowship in Pediatric Hematology/Oncology in the Children's Hospital/Dana-Farber Cancer Institute.
- EA Mullen. Pediatric Renal Tumors: Pediatric Nephrology, 6th Edn. Vol 2. Springer-Verlag Berlin Heidelberg Publishing, 2009.
- M Metzger, C Stewart, B Freeman, III, C Billups, F Hoffer, J Wu, M Coppes, R Grant, M Chintagumpala, EA Mullen, C Alvarado, N Daw, J Dome. Topotecan Is Active Against Wilms' Tumor: Results of a Multi-Institutional Phase II Study. Journal of Clinical Oncology. 2007: Volume 25, No 21 (July 20): 3130-3136